The Alliance for Regenerative Medicine Releases Agenda for Fourth Annual Cell & Gene Therapy Investor Day

– March 8, 2016

WASHINGTON, DC, March 8, 2016 – The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its upcoming fourth annual Cell & Gene Therapy Investor Day, taking place March 22, 2016 in New York City. This event, co-hosted by Piper Jaffray, is expected to attract 350+ attendees, including credentialed investors, members of the media and leading sector executives.

This event, featuring 30+ company presentations and five expert-led sessions, is the only investor conference specifically focused on gene therapy, cell therapy and other regenerative medicine products, providing institutional, strategic and venture investors unique access to the field’s most promising companies.

“Regenerative medicine, including gene editing, gene therapy, immuno-oncology and cellular therapy, continues to attract significant amounts of financial and strategic interest. Many of the companies working in these categories have achieved unprecedented clinical milestones, making the future for treating – or even curing – historically devastating diseases very promising,” said Jim Douglas, managing director, healthcare investment banking, Piper Jaffray. “Piper Jaffray is committed to supporting the companies in these important sectors of the biotech industry, which is why we are proud to be the lead sponsor of this event again in 2016.”  

2016 Panel Sessions and Speakers:

Fireside Chat: The Clinical Outlook for CAR-T Therapies for Hematological & Solid Tumor Malignancies
Edward Lanphier, Chairman, Alliance for Regenerative Medicine; President & CEO, Sangamo BioSciences (moderator)
Usman Azam, M.D., Global Head, Cell & Gene Therapies Unit, Novartis
Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, Stephen & Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center; Scientific Founder, Juno Therapeutics

Cell Therapy Infrastructure & Manufacturing Requirements for Commercialization
Edward Tenthoff, Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Cindy Collins, CEO/General Manager, Purification & Analysis & Cell Therapy Businesses, GE Healthcare
Bruce Levine, Ph.D., Barbara & Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
Robert Preti, Ph.D., Co-Founder & President, PCT, a Caladrius Company; SVP, Manufacturing & Technical Operations, CTO & Director, Caladrius Biosciences
David Sourdive, Ph.D., EVP, Corporate Development, Cellectis

Fireside Chat: Capital Markets & Attracting Institutional Interest
James Douglas, Managing Director, Healthcare Investment Banking, Piper Jaffray (moderator)
Ben Auspitz, Partner, F-Prime Capital Partners
Thomas Woiwode, Ph.D., Managing Director, Versant Ventures

Corporate Partnering to Build Valuable, Sustainable Clinical Pipelines in Gene & Cell Therapy
Jason Kolbert, Senior Managing Director & Head of Healthcare Research, Maxim Group (moderator)
Usman Azam, M.D., Global Head, Cell & Gene Therapies Unit, Novartis
Seng Cheng, Ph.D., Global Head of Research, Rare Diseases & Gene Therapy, Sanofi
Jeff Till, Ph.D., Director, External Innovation, EMD Serono
Mark Zimmerman, Ph.D., VP & Venture Leader, Janssen R&D

Optimization of Gene Therapies: Consideration of Platform Technologies
Joshua Schimmer, M.D., Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
David Kirn, M.D., Chairman & CEO, 4D Molecular Therapeutics
John Leonard, M.D., Chief Medical Officer, Intellia Therapeutics
Steven Paul, M.D., President & CEO, Voyager Therapeutics
David Venables, CEO, Synpromics

2016 Presenting Companies:
4D Molecular Therapeutics, Abeona Therapeutics, AGTC, Argos Therapeutics, Athersys, Avalanche Biotechnologies, Bellicum Pharmaceuticals, BioLife Solutions, bluebird bio, BrainStorm Cell Therapeutics, Capricor Therapeutics, Celyad, Cesca Therapeutics, Fate Therapeutics, Fibrocell, GenSight, Histogenics, Inovio Pharmaceuticals, Lion Biotechnologies, Mesoblast, MiMedx, Osiris Therapeutics, Oxford BioMedica, Pluristem Therapeutics, REGENXBIO, ReNeuron, Sangamo BioSciences, TxCell, uniQure, VBL Therapeutics, ViaCyte, Voyager Therapeutics

In addition to the event’s co-host Piper Jaffray and supporting bank, Maxim Group, sponsors include BioLife Solutions; Cryoport; Kawasaki; Lonza; and PCT, a Caladrius company. For more information please visit the event’s website at

Credentialed investors, life science strategic partners and members of the media can indicate their interest in attending here. Members of the media interested in attending should contact Lyndsey Scull at

The event will be held March 22, 2016, beginning at 7:30am at the Metropolitan Club at One East 60th Street in New York City.

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit